Cn /En

News Center

——

Company news

Industry news

InnoModels Biotechnology: Exploring the Innovative Path of Humanized Models of the Immune System

Author:

InnoModels

Release time:

2025-01-17

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients.
The core competence of InnoModels lies in its leading technology of humanized immune system model. By transplanting human immune cells or precursor cells into mice, InnoModels has successfully rebuilt the human immune system in mice, and this technological breakthrough has provided strong support for the development of tumor immunity drugs. Among them, the PBMC model (human peripheral blood mononuclear cell model) is the best work of InnoModels.
As an important technological achievement of InnoModels, PBMC model has multiple advantages such as high stability, multi-cell reconstruction and close to human body concentration. In the experiment, the success rate of PBMC model can reach more than 85%, and the reconstruction process is extremely stable, which ensures the reliability of the experimental data. At the same time, the model can reconstruct a variety of immune cells, including T cells, B cells, NK cells, macrophages, DC cells, etc., which provides a more realistic environment for drug testing. In addition, the reconstructed number of immune cells in the PBMC model can reach or approach the concentration of immune cells in the human body, further improving the accuracy of drug testing.
In addition to the PBMC model, InnoModels Biotechnology has also launched several sub-platforms targeting specific immune cell types, such as the iHuPBMC-T platform designed specifically for T-cell immunotherapy, the iHuPBMC-NK platform capable of reconstructing NK cells at the clinical level, and the iHuPBMC-B platform that can reconstruct B lymphocytes with antibody secretion function. The launch of these sub-platforms not only enriches the product line of InnoModels Biotechnology, but also provides customers with more precise and efficient solutions.

It is worth mentioning that InnoModels Biotechnology has also achieved remarkable results in the field of dual-source models. By combining the PBMC model with the PDX model, InnoModels has successfully constructed a practical PBMC-PDX two-person derivatization model. This model can realize the cellular and tissue level reconstruction of human immune system and tumor in mice, and has a high degree of model versatility, which can target almost all types of tumor immunotherapy. The birth of this achievement has undoubtedly injected new vitality into tumor immunity research.
In addition to scientific research and innovation, InnoModels Biotechnology is also actively involved in social services. With its stable and rapid modeling capability, as well as its unique dual humanized model with independent intellectual property rights, the company has taken a path with differentiated advantages in the segment of preclinical CRO services. InnoModels Biotechnology is committed to providing customers with the highest quality services and solutions, and jointly creating a new era of tumor immunology drug discovery and development.
Looking ahead, InnoModels Biotechnology will continue to leverage its technological advantages in animal models of the immune system to establish more models of different disease types and expand the scope of support provided by the company's CRO platform. At the same time, InnoModels Biotechnology will also continue to promote the performance iteration of dual humanized models in tumor immunity, and upgrade the versatility of the platform by improving the piggybacking and adaptability of the information, so as to provide better services for innovative drug R&D companies.
In conclusion, with its excellent technical strength, rich product line and efficient service quality, InnoModels Biotechnology has set a new benchmark in the field of humanized models of the immune system. We have reason to believe that in the future development, InnoModels Biotechnology will continue to lead the industry forward and contribute more wisdom and strength to the research and development of tumor immunity drugs.

None

Overview of iHuPBMC-T Technology from InnoModels Biotechnology

None

Overview of iHuPBMC-T Technology from InnoModels Biotechnology

Chuangmo Biotechnology (Beijing) Co., Ltd.

Telephone:+8615010000264 +8613810723384
E-mail:cndw@imodels.tech
Address: Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Chuangmo Biotechnology (Beijing) Co., Ltd

SEO

Business License